FINLAND/UK - VC-backed Ark Therapeutics awards management

The company's remuneration committee has awarded options to the CEO, Dr Nigel Parker, and to the chief finance officer, Martyn Williams,under the company's unapproved share option plan and the long term incentive plan. Dr Parker was awarded 580,000 options in total and Williams 225,000.

In 2004, Ark Therapeutics was listed on AIM in London. The company was formed when London-based genetic medicine business, Eurogene, acquired Finnish gene therapy company, Oy Quattrogene, in February 2001. Ark Therapeutics received a £14.5m round of funding in September 2001 from a large syndicate of investors including new investors BankInvest, Gartmore Asset Management and Northern Venture Managers, and existing investors Merlin, Nomura, Mountcashel, Techno Venture Management, BioFund Management and Concordia.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• UK / Ireland